Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

MetaVia Inc.

NASDAQ: MTVA · Life Sciences · 8 alerts · CIK 1638287

Share price
$1.21Close, Nov 16
Market cap
$8.13M
Shares outstanding
6.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MetaVia Inc. filings on SEC EDGAR ↗

9:01 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced the completion of the final patient visit in its Phase 1 Part 3A study of DA-1726, a dual GLP-1/glucagon receptor agonist. The company also highlighted interim Part 3B data showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, with full data from both parts expected in Q1 2027.

9:02 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia presented positive preclinical data at ObesityWeek® 2026 comparing its dual-receptor agonist DA-1726 against retatrutide in diet-induced obese mice. The study showed DA-1726 achieved comparable weight loss with less appetite suppression and superior glucose lowering, while significantly increasing hepatic FGF21 expression. The company plans to advance DA-1726 into a Phase 2 study for MetALD and ALD in the second half of 2027.

8:42 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced additional positive data from Part 3B of its Phase 1 clinical trial of DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks. These results complement previously reported data showing a 68.1% reduction in liver fat and 13.5% weight loss, supporting the drug's advancement into a Phase 2 study for MetALD and ALD planned for late 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.